Objetivo
The first product that AURA will launch to the market will be OSCANN, a diagnosis platform that will allow better, faster
and more accurate diagnosis of neurological disorders affecting Europe’s population in general, but specially youngsters
(e.g. ADHD) and elders (e.g. Parkinson). OSCANN allows for the measurement and analysis of ocular and oculocephalic
movements (OM/OCM) and combines the result with data obtained from other sources (clinical histories, medical
explorations, complementary tests and biomarkers) using Artificial Intelligence (AI) techniques to improve significantly the
quality of medical diagnosis in early stages.
Ámbito científico
- natural sciencescomputer and information sciencesartificial intelligence
- natural sciencescomputer and information sciencessoftware
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- medical and health sciencesclinical medicinepsychiatry
- medical and health sciencesbasic medicineneurologyparkinson
Programa(s)
- H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
- H2020-EU.3.1.4. - Active ageing and self-management of health
- H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
- H2020-EU.3.1.6. - Health care provision and integrated care
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEINST-1-2016-2017
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
28045 MADRID
España
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.